So Top Line data for acne in Q3 and AD in Q4.............with no safety issues identified for 1503....and dermatologists running the acne trials "positive".
1308 results early Q2 also.............very exciting.
BTX1801 targeted to Staph Aureus and MRSA............."MRSA accounts for ~59% of skin and soft tissue infections (SSTIs) presenting to the emergency department"............
They have narrowed the 1801 focus nicely I think and are looking to target the biggest possible mkt.........second half of this year will be huge for BOT if both 1204 and 1503 results are as good as, or better, than initial phase 1 trials......
Ann: 2019 Outlook Presentation, page-5
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.005(1.59%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.5¢ | 31.0¢ | $1.169M | 3.655M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 274982 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 48600 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
